Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AstraZeneca PLC
AZN
$164.74
Name : AstraZeneca PLC
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $255,485,181,952.00
EPSttm : 6.68
finviz dynamic chart for AZN
AstraZeneca PLC
$164.74
0.13%
$0.215
AZN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.12

Margin Of Safety %

9

Put/Call OI Ratio

0.59

EPS Next Q Diff

EPS Last/This Y

3.49

EPS This/Next Y

1.49

Price

164.91

Target Price

215.91

Analyst Recom

1.5

Performance Q

-10.67

Upside

-10.8%

Beta

0.3

Ticker: AZN




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-21AZN169.340.930.0663162
2026-07-22AZN169.770.890.3864812
2026-07-23AZN168.290.880.8165042
2026-07-24AZN169.090.890.4665010
2026-07-27AZN169.70.890.6065678
2026-07-28AZN172.510.891.2866786
2026-07-29AZN173.30.900.1167376
2026-07-30AZN171.360.860.4568998
2026-07-31AZN169.610.860.5969691
2026-08-03AZN157.970.860.1769788
2026-08-04AZN155.570.570.1399135
2026-08-05AZN161.460.550.19104601
2026-08-06AZN161.020.590.67102206
2026-08-07AZN161.410.610.95102786
2026-08-10AZN162.320.600.54103029
2026-08-11AZN158.710.600.45103498
2026-08-12AZN158.450.590.45104732
2026-08-13AZN157.230.581.73105229
2026-08-14AZN156.470.610.45107915
2026-08-17AZN156.920.600.23109321
2026-08-18AZN160.080.580.56109419
2026-08-19AZN164.40.590.26109536
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-21AZN169.27- 3794.77.64
2026-07-22AZN169.77- 3410.37.64
2026-07-23AZN168.24- 3058.87.64
2026-07-24AZN169.01- 3153.47.64
2026-07-27AZN169.71- 3319.07.64
2026-07-28AZN172.51- 4255.07.64
2026-07-29AZN173.29- 4724.87.64
2026-07-30AZN171.36- 4020.87.64
2026-07-31AZN169.63- 4286.07.63
2026-08-03AZN157.99- 3134.57.63
2026-08-04AZN157.99- 3134.57.63
2026-08-05AZN161.46- 4811.210.09
2026-08-06AZN161.02- 4145.810.09
2026-08-07AZN161.38- 4476.210.09
2026-08-13AZN157.22- 4200.110.09
2026-08-14AZN156.43- 4122.810.09
2026-08-17AZN156.91- 4540.010.09
2026-08-18AZN160.09- 4662.410.09
2026-08-19AZN164.91- 4807.810.09
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-21AZN-0.02-8.290.10
2026-07-22AZN-0.02-8.290.10
2026-07-23AZN-0.02-8.290.10
2026-07-24AZN-0.02-8.290.10
2026-07-27AZN0-8.590.17
2026-07-28AZN0-8.590.17
2026-07-29AZN-0.02-8.590.17
2026-07-30AZN-0.02-8.590.17
2026-07-31AZN-0.02-8.590.17
2026-08-03AZN-0.02-8.440.17
2026-08-04AZN-0.02-8.440.17
2026-08-05AZN-0.02-8.440.17
2026-08-06AZN-0.02-8.440.17
2026-08-07AZN-0.02-8.440.17
2026-08-10AZN-0.02-7.350.17
2026-08-11AZN-0.02-7.350.17
2026-08-12AZN-0.02-7.350.12
2026-08-13AZN-0.02-7.350.12
2026-08-14AZN-0.02-7.350.12
2026-08-17AZN-0.02-3.820.12
2026-08-18AZN-0.02-3.820.12
2026-08-19AZN-0.02-3.820.12
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

2.63

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

-0.02

Institutional Transactions

-3.82

Beta

0.3

Average Sales Estimate Current Quarter

16059

Average Sales Estimate Next Quarter

16605

Fair Value

180.55

Quality Score

94

Growth Score

96

Sentiment Score

96

Actual DrawDown %

22.5

Max Drawdown 5-Year %

-28.7

Target Price

215.91

P/E

24.65

Forward P/E

14.33

PEG

1.21

P/S

4.17

P/B

5.09

P/Free Cash Flow

23.53

EPS

6.69

Average EPS Est. Cur. Y​

10.09

EPS Next Y. (Est.)

11.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

17.02

Relative Volume

1.29

Return on Equity vs Sector %

-5.9

Return on Equity vs Industry %

-15.3

EPS 1 7Days Diff

2.4

EPS 1 30Days Diff

3.22

EBIT Estimation

4807.8
AZN Healthcare
$164.93
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
2/20
Pullback
15/25
Volume
1/15
Valuation
18/20
TP/AR
2/10
Options
5/10
RSI
49.6
Range 1M
56%
Sup Dist
3.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
33 /100
WEAK
Momentum
1/25
Growth
15/30
Estimates
6/20
Inst/Vol
3/15
Options
8/10
EPS Yr
11.8%
EPS NY
12.4%
52W%
29.5%
💎
Long-Term Value
Quality companies, undervalued
55 /100
WATCH
🟢 BUY +36.3% upside
Quality
22/30
Valuation
14/30
Growth
14/25
Stability
4/10
LT Trend
1/5
Upside
+36.3%
Quality
94
MoS
9%
AZN — P/E HistoricalDrug Manufacturers - General
AstraZeneca PLC
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 96100
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN

Latest News

Caricamento notizie per AZN
stock quote shares AZN – AstraZeneca PLC Stock Price stock today
news today AZN – AstraZeneca PLC stock forecast ,stock prediction 2023 2024 2025
marketwatch AZN – AstraZeneca PLC yahoo finance google finance
stock history AZN – AstraZeneca PLC invest stock market
stock prices AZN premarket after hours
ticker AZN fair value insiders trading